

Elarekibep

Cat. No.:	HY-P99935
CAS No.:	2485020-60-6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma ^[1] .									
In Vitro	<p>Elarekibep (PRS-060) (0-10 μM) inhibits IL-4- or IL-13-induced STAT-6 phosphorylation with IC₅₀ values of 0.12 nM and 0.10 nM, respectively^[1].</p> <p>PRS-060 (0-10 μM) inhibits hIL-4 or hIL-13 induced proliferation of TF-1 cells with IC₅₀ values of 0.87 nM and 0.92 nM, respectively^[1].</p> <p>PRS-060 (0-10 μM) inhibits hIL-13 induced human epithelial cell mucus transdifferentiation with an IC₅₀ value of 0.3 nM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>PRS-060 (i.t; 2, 10, 50 μg) inhibits IL-13-induced eotaxin-1 expression in the lung and ovalbumin-induced acute allergic inflammation in the humanized mouse^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Triple-humanized mouse model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2, 10, 50 μg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intratracheal instillation (i.t)</td> </tr> <tr> <td>Result:</td> <td>Strongly suppressed acute allergic inflammation indices in triple humanized mice.</td> </tr> </table>		Animal Model:	Triple-humanized mouse model ^[1]	Dosage:	2, 10, 50 μ g/mouse	Administration:	Intratracheal instillation (i.t)	Result:	Strongly suppressed acute allergic inflammation indices in triple humanized mice.
Animal Model:	Triple-humanized mouse model ^[1]									
Dosage:	2, 10, 50 μ g/mouse									
Administration:	Intratracheal instillation (i.t)									
Result:	Strongly suppressed acute allergic inflammation indices in triple humanized mice.									

REFERENCES

[1]. Gabriele Matschiner, et al. Elarekibep (PRS-060/AZD1402): a new class of inhaled Anticalin medicine targeting IL-4Ra for T2 endotype asthma. J Allergy Clin Immunol. 2022 Dec 30;S0091-6749(22)02588-X.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA